Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.


TSX:SVA - Post by User

Comment by Stockfshron May 31, 2022 1:11am
111 Views
Post# 34718972

RE:RE:RE:RE:RE:TSX Uplisting Expectations

RE:RE:RE:RE:RE:TSX Uplisting ExpectationsRe: Warrant overhang
If I am reading things right (please let me know if you see an error here) there could be as many as 12.2 million warrants exercisable at $0.35 and 23.4 million warrants exercisable at $0.30 expiring this September. After that we have 16.7 million warrants at $1.70 expiring March 1, 2023. The good news is that this will bring in a significant amount of money into the company coffers. The bad news is this is a sh#t ton of overhang since many investors will sell their stock in order to raise funds to exercise the warrants. Then there is the dilution. Then there are the management incentive warrants and DSUs that will add about 38.7 million common shares worth of dilution at some point.
So it looks like the worst overhang will be until this September. After that, price pressure on the stock should start to relax, all things being equal. IMHO
<< Previous
Bullboard Posts
Next >>